Hamilton and Toronto, Ontario, Canada From the Michael G. DeGroote School of Medicine and Clinical Epidemiology and Biostatistics, McMaster University, and the Division of Plastic Surgery/Wound Care, St. Michael's Hospital, University of Toronto.
Plast Reconstr Surg. 2012 Jul;130(1):67e-77e. doi: 10.1097/PRS.0b013e318254b19f.
Management of pressure sores poses a significant reconstructive challenge for plastic surgeons. Currently, there is no consensus on whether musculocutaneous, fasciocutaneous, or perforator-based flaps provide superior results for treating pressure sores.
The following databases were searched: Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, LILACS (January of 1950 to November of 2010), MEDLINE (January of 1950 to November of 2010), and EMBASE (January of 1980 to November of 2010). Only articles reporting on the use of musculocutaneous, fasciocutaneous, and perforator-based flaps were included. The primary study outcomes were complication and recurrence rates.
Fifty-five articles were included in the final analysis (kappa = 0.78). From this total, 28 were categorized as pertaining to musculocutaneous flaps, 13 studied fasciocutaneous flaps, and 14 evaluated perforator-based flaps. The authors' review revealed recurrence and complication rates of 8.9 and 18.6 percent, respectively, following reconstruction with musculocutaneous flaps, 11.2 and 11.7 percent following reconstruction with fasciocutaneous flaps, and 5.6 and 19.6 percent following reconstruction with perforator-based flaps. Overall, statistical analysis revealed no significant difference in complication or recurrence rates among these three techniques.
The authors' review revealed that there was no statistically significant difference with regard to recurrence or complication rates among musculocutaneous, fasciocutaneous, or perforator-based flaps. This suggests that surgeons performing such reconstructive procedures may choose to consider the advantages of a specific approach rather than the complication and recurrence rates.
CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, IV.
压力性溃疡的处理对整形外科医生来说是一个重大的重建挑战。目前,对于治疗压力性溃疡,肌皮瓣、筋膜皮瓣和穿支皮瓣哪种方法的效果更好,尚无定论。
我们检索了以下数据库:Cochrane 系统评价数据库、Cochrane 对照试验中心注册库、LILACS(1950 年 1 月至 2010 年 11 月)、MEDLINE(1950 年 1 月至 2010 年 11 月)和 EMBASE(1980 年 1 月至 2010 年 11 月)。仅纳入报告肌皮瓣、筋膜皮瓣和穿支皮瓣应用的文章。主要研究结局为并发症和复发率。
最终有 55 篇文章纳入分析(kappa 值=0.78)。其中 28 篇归入肌皮瓣,13 篇归入筋膜皮瓣,14 篇归入穿支皮瓣。作者的综述结果显示,肌皮瓣重建后复发率和并发症发生率分别为 8.9%和 18.6%,筋膜皮瓣重建后分别为 11.2%和 11.7%,穿支皮瓣重建后分别为 5.6%和 19.6%。总体而言,统计学分析显示这 3 种技术在并发症和复发率方面无显著差异。
作者的综述结果显示,肌皮瓣、筋膜皮瓣和穿支皮瓣在复发率和并发症发生率方面无统计学差异。这表明,实施此类重建手术的外科医生可能会考虑选择特定方法的优势,而不是并发症和复发率。
临床问题/证据等级:治疗,IV 级。